polyclonal rabbit anti-human mdc (ccl22) antibody 500-p107  (PeproTech)

Journal: Translational Oncology

Article Title: CCL22 as an independent prognostic factor in endometrial cancer patients

doi: 10.1016/j.tranon.2024.102116

Figure Lengend Snippet: Representative images of CCL22-expression in EC: (A) intermediate expression in glandular cells (IRS=2.67), S/M (IRS=0.67); (B) high expression in glandular cells (IRS=12.00), S/M (IRS=5.33); (C) strongly positive cells in tumor distant S/M; (D) significant correlation between CCL22 in tumor- and stroma-cells; (E) CCL22 levels in tumor cells were higher than in S/M. Objective 20x, Scale bar 100 µm.

Article Snippet: Paraffin-embedded TMA of EC-patients and tissue of the control group were incubated with the polyclonal rabbit anti-human MDC (CCL22) antibody (500-P107 1:300, Peprotech) using ZytoChem Plus HRP Polymer System mouse/rabbit following the manufacturer's instructions.

Techniques: Expressing

Journal: Translational Oncology

Article Title: CCL22 as an independent prognostic factor in endometrial cancer patients

doi: 10.1016/j.tranon.2024.102116

Figure Lengend Snippet: Representative images of CCL22-expression in endometrial control with negative (A) and strong staining in glandular epithelial cells (B) and strongly positive cells in myometrium (C). Elevated CCL22-expression in glandular epithelial cells compared to stroma cells (D). Significantly lower CCL22-IRS EC compared to benign endometrium (E). Concerning CCL22 in S/M a trend to higher levels was found in the specimens of EC patients (F). Objective 20x, Scale bar 100 µm.

Article Snippet: Paraffin-embedded TMA of EC-patients and tissue of the control group were incubated with the polyclonal rabbit anti-human MDC (CCL22) antibody (500-P107 1:300, Peprotech) using ZytoChem Plus HRP Polymer System mouse/rabbit following the manufacturer's instructions.

Techniques: Expressing, Control, Staining

Journal: Translational Oncology

Article Title: CCL22 as an independent prognostic factor in endometrial cancer patients

doi: 10.1016/j.tranon.2024.102116

Figure Lengend Snippet: CCL22-expression in S/M increases with higher grade in EC (A). High CCL22-expression in S/M in EC is associated to poorer OS (B), but not to PFS (C). (D) High CCL22-expression in tumor epithelium is associated to prolonged OS, but not to PFS (E).

Article Snippet: Paraffin-embedded TMA of EC-patients and tissue of the control group were incubated with the polyclonal rabbit anti-human MDC (CCL22) antibody (500-P107 1:300, Peprotech) using ZytoChem Plus HRP Polymer System mouse/rabbit following the manufacturer's instructions.

Techniques: Expressing

Journal: Translational Oncology

Article Title: CCL22 as an independent prognostic factor in endometrial cancer patients

doi: 10.1016/j.tranon.2024.102116

Figure Lengend Snippet: Isolated CCL22+ cells were identified as mainly M1-macrophages in distant myometrial tissue areas by double immunofluorescence: (A) Representative EC stained for CCL22 (red) and CD68, CD80, CD163, and DEC205 (green); (B) Proportion of CCL22+ cells, that expressed also one of those immune cells markers is presented; (C) Proportion of total expression of all markers: dominant occurrence of CD68+ and CD80+ cells; (D) Kaplan-Meier Curve for OS and PFS (E). Correlation analysis of FoxP3 and CCL22 in S/M (F), distant strongly positive cells (G), and in tumor cells (H).

Article Snippet: Paraffin-embedded TMA of EC-patients and tissue of the control group were incubated with the polyclonal rabbit anti-human MDC (CCL22) antibody (500-P107 1:300, Peprotech) using ZytoChem Plus HRP Polymer System mouse/rabbit following the manufacturer's instructions.

Techniques: Isolation, Immunofluorescence, Staining, Expressing

Journal: Translational Oncology

Article Title: CCL22 as an independent prognostic factor in endometrial cancer patients

doi: 10.1016/j.tranon.2024.102116

Figure Lengend Snippet: High CCL22 secretion by freshly isolated PBMCs in contrast to EC cell lines without stimulation (A). Significantly increased CCL22 in SN after coculture of PBMCs and EC cell lines (B). The addition of tumor-SN to PBMCs led to a significant increase of CCL22 levels (C), while incubation of tumor cells with PBMC-SN resulted in a decrease in CCL22 levels (D). mRNA levels of tumor cells after coculture revealed a significant increase in CCL22 of Ishikawa+ with PBMCs (E). CCL22 levels of tumor RIPA lysates also revealed a significant increase after coculture (F). All experiments were carried out in technical triplicate and repeated three times with PBMCs from different blood donors.

Article Snippet: Paraffin-embedded TMA of EC-patients and tissue of the control group were incubated with the polyclonal rabbit anti-human MDC (CCL22) antibody (500-P107 1:300, Peprotech) using ZytoChem Plus HRP Polymer System mouse/rabbit following the manufacturer's instructions.

Techniques: Isolation, Incubation

Journal: Frontiers in Oncology

Article Title: Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma

doi: 10.3389/fonc.2019.00907

Figure Lengend Snippet: Intraperitoneally administered bexarotene modifies chemokine and cytokine expression in mouse EL4 T-cell lymphoma. Expression of chemokines and cytokines in EL4 T-cell lymphoma was analyzed by quantitative RT-PCR using the ΔCt method ( n = 5). Averages of five independent experiments are shown (A) . We subcutaneously injected 100 μl of 2 × 10 6 cells/ml of EL4 T-cell lymphoma cells, and intraperitoneally injected 0.15 mg bexarotene or 0.30 mg anti-CCL22 antibodies (R&D Systems, Minneapolis, MN) at day 6 and day 12 ( n = 5 for each treated group) Error bar represents ± standard deviation. (B) One representative experiment of two is shown * p < 0.05, ** p < 0.01. Error bar represents ± standard deviation.

Article Snippet: The following antibodies were used for immunofluorescence (IF): mouse anti-human CD163 phycoerythrin-conjugated monoclonal antibody (R&D Systems), rabbit polyclonal anti-CCL22 antibody (Biorbyt, Cambridge, UK), rabbit polyclonal anti-CXCL5 antibody (Lifespan Bioscience, Seattle, WA), mouse anti-CXCL10 antibody (Lifespan Bioscience), Alexa Fluor 488-conjugated anti-mouse rat immunoglobulin (Ig)G (Abcam, Tokyo, Japan), and Alexa Fluor 488-conjugated anti-rabbit goat IgG (Abcam).

Techniques: Expressing, Quantitative RT-PCR, Injection, Standard Deviation

Journal: Frontiers in Oncology

Article Title: Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma

doi: 10.3389/fonc.2019.00907

Figure Lengend Snippet: Serum levels of CCL22, CXCL5, and CXCL10 in early and advanced CTCL patients. Serum levels of CCL22, CXCL5, and CXCL10 were examined by ELISA in 9 early CTCL patients and 16 advanced CTCL patients. ** p < 0.01, Student's t -test; n.s ., not significant. Error bar represents ± standard deviation.

Article Snippet: The following antibodies were used for immunofluorescence (IF): mouse anti-human CD163 phycoerythrin-conjugated monoclonal antibody (R&D Systems), rabbit polyclonal anti-CCL22 antibody (Biorbyt, Cambridge, UK), rabbit polyclonal anti-CXCL5 antibody (Lifespan Bioscience, Seattle, WA), mouse anti-CXCL10 antibody (Lifespan Bioscience), Alexa Fluor 488-conjugated anti-mouse rat immunoglobulin (Ig)G (Abcam, Tokyo, Japan), and Alexa Fluor 488-conjugated anti-rabbit goat IgG (Abcam).

Techniques: Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Frontiers in Oncology

Article Title: Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma

doi: 10.3389/fonc.2019.00907

Figure Lengend Snippet: Serum levels of CCL22, CXCL5 and CXCL10 in patients treated with bexarotene. Serum levels of CCL22 (A) , CXCL5 (B) , and CXCL10 (C) in responders ( n = 5) and non-responders ( n = 5) at day 0 and day 28 were measured by ELISA. Error bar represents ± standard deviation. Change ratio is calculated described below: (post-treatment serum chemokine)/(pre-treatment serum chemokine level) × 100 (%). Change ratios of serum CCL22 (A) , CXCL5 (B) , and CXCL10 (C) in CTCL are calculated in each sample and the average are shown. Error bar represents ± standard deviation. ** p < 0.01, Mann–Whitney U -test; n.s ., not significant.

Article Snippet: The following antibodies were used for immunofluorescence (IF): mouse anti-human CD163 phycoerythrin-conjugated monoclonal antibody (R&D Systems), rabbit polyclonal anti-CCL22 antibody (Biorbyt, Cambridge, UK), rabbit polyclonal anti-CXCL5 antibody (Lifespan Bioscience, Seattle, WA), mouse anti-CXCL10 antibody (Lifespan Bioscience), Alexa Fluor 488-conjugated anti-mouse rat immunoglobulin (Ig)G (Abcam, Tokyo, Japan), and Alexa Fluor 488-conjugated anti-rabbit goat IgG (Abcam).

Techniques: Enzyme-linked Immunosorbent Assay, Standard Deviation, MANN-WHITNEY

Journal: Frontiers in Oncology

Article Title: Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma

doi: 10.3389/fonc.2019.00907

Figure Lengend Snippet: CCL22 producing cells in the lesional skin of MF. Representative paraffin-embedded tissue samples from the lesional skin at each stage of MF. Sections were deparaffinized and stained using anti-CCL22 or anti-CXCL5 antibodies. Three representative high-power fields of each section were selected from dermis associated with a dense dermal lymphoid infiltrate. Sections were developed with 3-Amino-9-ethylcarbazole. The percentage of CCL22 + and CXCL5 + cells was calculated as follows: CCL22 + cells or CXCL5 + cells/hematoxylin-positive cells × 100. Quantification of percentages of CCL22 + cells and CXCL5 + cells from 9 early CTCL patients and 16 advanced CTCL patients is shown. Scale bar, 100 μm. Error bar represents ± standard deviation (A) . IF staining of CTCL for CCL22 (green), CD163 (red), and DAPI (blue, nuclei), and CXCL5 (green), CD163 (red), and DAPI (blue, nuclei). A merged image is also shown, with green and red combining into yellow. The isotype control IgG1 stains as red or green. Scale bar, 20 μm (B) . Representative specimens from three cases are shown. The number of immunoreactive cells was counted at a magnification of × 400. The average of three independent fields in each sample was calculated (* p < 0.05). Error bar represents ± standard deviation.

Article Snippet: The following antibodies were used for immunofluorescence (IF): mouse anti-human CD163 phycoerythrin-conjugated monoclonal antibody (R&D Systems), rabbit polyclonal anti-CCL22 antibody (Biorbyt, Cambridge, UK), rabbit polyclonal anti-CXCL5 antibody (Lifespan Bioscience, Seattle, WA), mouse anti-CXCL10 antibody (Lifespan Bioscience), Alexa Fluor 488-conjugated anti-mouse rat immunoglobulin (Ig)G (Abcam, Tokyo, Japan), and Alexa Fluor 488-conjugated anti-rabbit goat IgG (Abcam).

Techniques: Staining, Standard Deviation, Control

Journal: Frontiers in Oncology

Article Title: Bexarotene Reduces Production of CCL22 From Tumor-Associated Macrophages in Cutaneous T-Cell Lymphoma

doi: 10.3389/fonc.2019.00907

Figure Lengend Snippet: Production of CCL22 from M2 macrophages treated with bexarotene. Culture supernatant from M2 macrophages was harvested as described in section Materials and Methods and measured by ELISA ( n = 3). Data from each donor were obtained from triplicate assays, and mean ± SD was calculated. Representative data from at least three independent experiments are shown. ** p < 0.01, Mann–Whitney U -test; n.s ., not significant. Error bar represents ± standard deviation (A) . M-CSF-induced M2 macrophages from PBMCs: the expression of CD163 and arginase 1 was examined by flow cytometry (B) .

Article Snippet: The following antibodies were used for immunofluorescence (IF): mouse anti-human CD163 phycoerythrin-conjugated monoclonal antibody (R&D Systems), rabbit polyclonal anti-CCL22 antibody (Biorbyt, Cambridge, UK), rabbit polyclonal anti-CXCL5 antibody (Lifespan Bioscience, Seattle, WA), mouse anti-CXCL10 antibody (Lifespan Bioscience), Alexa Fluor 488-conjugated anti-mouse rat immunoglobulin (Ig)G (Abcam, Tokyo, Japan), and Alexa Fluor 488-conjugated anti-rabbit goat IgG (Abcam).

Techniques: Enzyme-linked Immunosorbent Assay, MANN-WHITNEY, Standard Deviation, Expressing, Flow Cytometry